Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics, Inc. (DE:2090)
:2090
2090 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.74 - €4.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€255.79M
Enterprise Value€277.07M
Total Cash (Recent Filing)-$30.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
May 08, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding56,434,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
€23.23Price Target Upside390.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Astria Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 3 ALPHA-ORBIT trial with navenibart for hereditary angioedema (HAE) presents a promising prophylactic therapy.
Drug EfficacyNew data from the Phase 1b/2 ALPHA-STAR trial show navenibart reduced moderate-to-severe HAE attacks by 95%-96% and rescue medication use by 91%-94% after six months, which compares favorably to other HAE injectables with more onerous dosing.
Financial OutlookAstria ended the quarter financially strong with $328.1 million in cash, which management believes will be sufficient to fund its current operating plan into mid-2027.
Bears Say
Cash BurnAnnualized cash burn is significant, with a burn rate of $117 million and approximately 2.5 years of cash remaining.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.96% Insiders
18.51%
Mutual Funds
0.02% Other Institutional Investors
59.21% Public Companies and
Individual Investors
2090 FAQ
What was Astria Therapeutics, Inc.’s price range in the past 12 months?
Astria Therapeutics, Inc. lowest stock price was €4.74 and its highest was €4.74 in the past 12 months.
What is Astria Therapeutics, Inc.’s market cap?
Astria Therapeutics, Inc.’s market cap is €255.79M.
When is Astria Therapeutics, Inc.’s upcoming earnings report date?
Astria Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were Astria Therapeutics, Inc.’s earnings last quarter?
Astria Therapeutics, Inc. released its earnings results on Mar 11, 2025. The company reported -€0.387 earnings per share for the quarter, beating the consensus estimate of -€0.397 by €0.011.
Is Astria Therapeutics, Inc. overvalued?
According to Wall Street analysts Astria Therapeutics, Inc.’s price is currently Undervalued.
Does Astria Therapeutics, Inc. pay dividends?
Astria Therapeutics, Inc. does not currently pay dividends.
What is Astria Therapeutics, Inc.’s EPS estimate?
Astria Therapeutics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Astria Therapeutics, Inc. have?
Astria Therapeutics, Inc. has 56,434,220 shares outstanding.
What happened to Astria Therapeutics, Inc.’s price movement after its last earnings report?
Astria Therapeutics, Inc. reported an EPS of -€0.387 in its last earnings report, beating expectations of -€0.397. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astria Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:2090
---
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.23 (390.14% Upside)
€23.23 (390.14% Upside)
Blogger Sentiment
Bullish
DE:2090 Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.62%
12-Months-Change
Fundamentals
Return on Equity
-33.52%
Trailing 12-Months
Asset Growth
34.44%
Trailing 12-Months
Company Description
Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
---
2090 Stock 12 Month Forecast
Average Price Target
€23.23
▲(390.14% Upside)
Technical Analysis
Palvella Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Humacyte
―
Candel Therapeutics
―
Best Analysts Covering 2090
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+14.07%
reiterated a buy rating 9 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +14.07% per trade.
---